Comparative biomarker profiles of pacritinib, momelotinib, pexidartinib, and ruxolitinib using BioMAP Diversity PLUS panel. (December 2016) - Al-Fayoumi, S.; Watson, R.; O'Mahony, A.; Singer, J.W.